Business
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected ...
About this update from Bioinvent International Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden.","length":496,"tagName":"p"},{"type":"text","content":"Poster Presentation","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT)","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: EHA2026 Congress, Stockholm","length":37,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":337,"olType":false},{"type":"text","content":"The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma. BI-1206 directly targets FcγRIIB-mediated rituximab internalization, a major driver of resistance to CD20-directed therapy, while leveraging BTK inhibition with acalabrutinib to enhance anti-tumor activity.","length":508,"tagName":"p"},{"type":"text","content":"BioInvent will host a KOL event at GT30, Grev Turegatan 30 in Stockholm on June 11, more information to follow within short.","length":124,"tagName":"p"},{"type":"text","content":"About the BI-1206 Phase 2a part of the studyThe triple combination arm in the ongoing Phase 2a part of the study (NCT03571568) combines the subcutaneous formulation of BI-1206 with rituximab and acalabrutinib in subjects with indolent B-cell non-Hodgkin's lymphoma (NHL) who have relapsed or are refractory to...